247 related articles for article (PubMed ID: 33789884)
1. Update to living WHO guideline on drugs for covid-19.
BMJ; 2021 Mar; 372():n860. PubMed ID: 33789884
[No Abstract] [Full Text] [Related]
2. Update to living systematic review on drug treatments for covid-19.
BMJ; 2021 Mar; 372():n858. PubMed ID: 33789885
[No Abstract] [Full Text] [Related]
3. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Lawrence JM; Meyerowitz-Katz G; Heathers JAJ; Brown NJL; Sheldrick KA
Nat Med; 2021 Nov; 27(11):1853-1854. PubMed ID: 34552263
[No Abstract] [Full Text] [Related]
4. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
5. Ivermectin in COVID-19: What do we know?
Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
[No Abstract] [Full Text] [Related]
6. Update to living WHO guideline on drugs for covid-19.
BMJ; 2020 Dec; 371():m4779. PubMed ID: 33334781
[No Abstract] [Full Text] [Related]
7. Long-term consequences of the misuse of ivermectin data.
Alvarez-Moreno C; Cassell JA; Donkor CM; Head MG; Middleton J; Pomat W; Saka B; Yirgu R
Lancet Infect Dis; 2021 Dec; 21(12):1624-1626. PubMed ID: 34672962
[No Abstract] [Full Text] [Related]
8. COVID-19 Pandemic and Dysbiosis: Can the Ivermectin Hysteria Lead to an Increase of Autoimmune Neuroinflammatory Diseases?
Peron JPS; Nakaya HI; Schlindwein MAM; Gonçalves MVM
Crit Rev Immunol; 2020; 40(6):537-542. PubMed ID: 33900697
[TBL] [Abstract][Full Text] [Related]
9. Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19.
Temple C; Hoang R; Hendrickson RG
N Engl J Med; 2021 Dec; 385(23):2197-2198. PubMed ID: 34670041
[No Abstract] [Full Text] [Related]
10. Update to living WHO guideline on drugs for covid-19.
BMJ; 2021 Sep; 374():n2219. PubMed ID: 34556469
[No Abstract] [Full Text] [Related]
11. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
12. Update to living WHO guideline on drugs for covid-19.
BMJ; 2020 Nov; 371():m4475. PubMed ID: 33214213
[No Abstract] [Full Text] [Related]
13. Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
Kow CS; Hasan SS
Am J Ther; 2021 Aug; 28(5):e616-e619. PubMed ID: 34387564
[No Abstract] [Full Text] [Related]
14. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
15. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.
Kow CS; Merchant HA; Mustafa ZU; Hasan SS
Pharmacol Rep; 2021 Oct; 73(5):1473-1479. PubMed ID: 33779964
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
[No Abstract] [Full Text] [Related]
17. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
Zein AFMZ; Sulistiyana CS; Raffaelo WM; Pranata R
Diabetes Metab Syndr; 2021; 15(4):102186. PubMed ID: 34237554
[TBL] [Abstract][Full Text] [Related]
18. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
Roche D; O'Connor C; Murphy M
Clin Exp Dermatol; 2021 Oct; 46(7):1327-1328. PubMed ID: 33896010
[No Abstract] [Full Text] [Related]
19. Flawed ivermectin preprint highlights challenges of COVID drug studies.
Reardon S
Nature; 2021 Aug; 596(7871):173-174. PubMed ID: 34341573
[No Abstract] [Full Text] [Related]
20. Update to living WHO guideline on drugs for covid-19.
BMJ; 2022 Jan; 376():o80. PubMed ID: 35027394
[No Abstract] [Full Text] [Related]
[Next] [New Search]
